Imugene (ASX: IMU) doses first patient in combination cohort of IMPRINTER study

June 01, 2023 11:12 AM AEST | By Ankit Sethi
Follow us on Google News:


  • IMU, an Australian immuno-oncology company, has dosed first patient in the combination cohort of IMPRINTER study
  • Imugene’s study assesses safety, efficacy, and optimal dose of PD1-Vaxx combined with atezolizumab in NSCLC patients
  • IMU-201 (PD1-Vaxx) study will be undertaken at sites in the US and Australia

ASX-listed immuno-oncology company Imugene Limited (ASX: IMU) has announced about the dosing of the first patient in the combination cohort of the IMPRINTER study. This clinical trial by Imugene is about evaluating the safety and efficacy of the company's PD1-Vaxx, alone or in combination with atezolizumab, in patients suffering from non-small cell lung cancer (NSCLC).

Notably, PD1-Vaxx is a B-cell activating immunotherapy. Atezolizumab (Tecentriq®) is an immune checkpoint inhibitor from Roche that targets PD-L1.

The development

Imugene has dosed the first patient in the combination cohort as part of a clinical trial, which is evaluating the safety and efficacy of IMU-201 (PD1-Vaxx) either alone or when combined with atezolizumab (Tecentriq®). The company states that the objective of the open label, multi-centre (sites in Australia and the US), dose escalation/expansion phase 1/1b trial is to evaluate safety, efficacy, and optimal dose of the PD1-Vaxx and atezolizumab combination.

The dual targeting of the PD-1/PD-L1 axis is being studied, providing treatment options for cancer patients. Combination with PD1-Vaxx may help in overcoming treatment resistance to ICIs, thereby extending the benefit of atezolizumab, according to Imugene.

It is also stated that Tecentriq® is the first approved cancer immunotherapy for adjuvant NSCLC. It has shown “clinically meaningful benefit” in different types of lung cancer. Six currently approved indications have been shown in the US.

Data source: Company update

The sponsor of the ongoing study is Imugene Limited, with Roche providing atezolizumab. No preconditions apply to the current supply agreement, which is for up to five years (unless agreed otherwise by either party with industry standard cancellation provisions). Rights to all inventions and discoveries related to the combination would belong to both the study partners.

IMU shares traded at AU$0.105 (market cap over AU$706 million) at the time of writing on 1 June 2023.


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Top ASX Listed Companies

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK